PFAM Search:   
       by Pfam accession/ID, keyword
QuickSearch:   
by PDB,NDB,UniProt,PROSITE Code or Search Term(s)  

Full view: branches of nodes matching the query are shown completely (Compact view)

(use 'Shift Left-Click' to collapse/expand all levels downwards; use 'Control Left-Click' to collapse/expand all levels upwards)
 
(-)
Clan: Peptidase_PA (797)
(-)
Family: Peptidase_C3 (11)
(-)
Coxsackievirus B3 (strain Nancy) (6)
2VB0A:1-166CRYSTAL STRUCTURE OF COXSACKIEVIRUS B3 PROTEINASE 3C
2ZTXA:1-166COMPLEX STRUCTURE OF CVB3 3C PROTEASE WITH EPDTC
2ZTYA:1-166CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP C2
2ZTZB:1-166; B:1-166CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP P21
2ZU1B:1-166; B:1-166CRYSTAL STRUCTURE OF CVB3 3C PROTEASE MUTANT C147A
2ZU3A:1-166COMPLEX STRUCTURE OF CVB3 3C PROTEASE WITH TG-0204998
(-)
Foot-and-mouth disease virus (strain A10-61) (Aphthovirus A) (FMDV) (2)
2WV4B:6-187; B:6-187CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION
2WV5D:7-187; D:7-187; D:7-187; D:7-187CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION WITH A GLN TO GLU SUBSTITUTION AT P1
(-)
Human enterovirus 71 (1)
3OSYE:1-166; E:1-166; E:1-166; E:1-166; E:1-166HUMAN ENTEROVIRUS 71 3C PROTEASE
(-)
Human hepatitis A virus genotype IB (isolate HM175) (HHAV) (Human hepatitis A virus (isolate Human/A (1)
1QA7D:3-196; D:3-196; D:3-196; D:3-196CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
(-)
Human rhinovirus 2 (HRV-2) (1)
2XYAA:1-166NON-COVALENT INHIBTORS OF RHINOVIRUS 3C PROTEASE.
(-)
Family: Peptidase_C30 (30)
(-)
Avian infectious bronchitis virus (strain M41) (IBV) (2)
2Q6DC:29-307; C:29-307; C:29-307CRYSTAL STRUCTURE OF INFECTIOUS BRONCHITIS VIRUS (IBV) MAIN PROTEASE
2Q6FB:29-302; B:29-302CRYSTAL STRUCTURE OF INFECTIOUS BRONCHITIS VIRUS (IBV) MAIN PROTEASE IN COMPLEX WITH A MICHAEL ACCEPTOR INHIBITOR N3
(-)
Human SARS coronavirus (SARS-CoV) (Severe acute respiratory syndrome coronavirus) (24)
2VJ1B:29-301; B:29-301A STRUCTURAL VIEW OF THE INACTIVATION OF THE SARS-CORONAVIRUS MAIN PROTEINASE BY BENZOTRIAZOLE ESTERS
2Q6GB:29-302; B:29-302CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE H41A MUTANT IN COMPLEX WITH AN N-TERMINAL SUBSTRATE
2QC2B:29-305; B:29-305CRYSTAL STRUCTURE OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) 3C-LIKE PROTEASE ASN214ALA MUTANT
2QCYA:29-306CRYSTAL STRUCTURE OF A MONOMERIC FORM OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS) 3C-LIKE PROTEASE MUTANT
2QIQA:29-301STRUCTURE-BASED DESIGN AND SYNTHESIS AND BIOLOGICAL EVALUATION OF PEPTIDOMIMETIC SARS-3CLPRO INHIBITORS
2V6NA:29-306CRYSTAL STRUCTURES OF THE SARS-CORONAVIRUS MAIN PROTEINASE INACTIVATED BY BENZOTRIAZOLE COMPOUNDS
2Z3CA:29-306A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE
2Z3EA:29-306A MECHANISTIC VIEW OF ENZYME INHIBITION AND PEPTIDE HYDROLYSIS IN THE ACTIVE SITE OF THE SARS-COV 3C-LIKE PEPTIDASE
1Q2WB:29-301; B:29-301X-RAY CRYSTAL STRUCTURE OF THE SARS CORONAVIRUS MAIN PROTEASE
1UJ1B:29-302; B:29-302CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO)
1UK3B:29-302; B:29-302CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) AT PH7.6
1UK4B:29-302; B:29-302CRYSTAL STRUCTURE OF SARS CORONAVIRUS MAIN PROTEINASE (3CLPRO) COMPLEXED WITH AN INHIBITOR
1WOFB:29-302; B:29-302CRYSTAL STRUCTURE OF SARS-COV MPRO IN COMPLEX WITH AN INHIBITOR N1
1Z1IA:29-301CRYSTAL STRUCTURE OF NATIVE SARS CLPRO
1Z1JB:1029-1306; B:1029-1306CRYSTAL STRUCTURE OF SARS 3CLPRO C145A MUTANT
2OP9B:29-301; B:29-301SUBSTRATE SPECIFICITY PROFILING AND IDENTIFICATION OF A NEW CLASS OF INHIBITOR FOR THE MAJOR PROTEASE OF THE SARS CORONAVIRUS
2Z94A:29-306COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH TDT
2Z9GA:29-306COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH PMA
2Z9JB:29-304; B:29-304COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH EPDTC
2Z9KB:29-306; B:29-306COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH JMF1600
2Z9LB:29-301; B:29-301COMPLEX STRUCTURE OF SARS-COV 3C-LIKE PROTEASE WITH JMF1586
3M3SB:29-302; B:29-302CRYSTAL STRUCTURE OF SARS-COV MAIN PROTEASE ASN214ALA MUTANT WITH AUTHORIZE N-TERMINUS
3M3TA:29-305SARS-COV MAIN PROTEASE MONOMERIC ARG298ALA MUTANT WITH N-TERMINAL ADDITIONAL RESIDUES (GLY-SER)
3M3VB:29-303; B:29-303SARS-COV MAIN PROTEASE TRIPLE MUTANT STI/A WITH TWO N-TERMINAL ADDITIONAL RESIDUE (GLY-SER)
(-)
Human coronavirus 229E (HCoV-229E) (2)
1P9SB:29-299; B:29-299CORONAVIRUS MAIN PROTEINASE (3CLPRO) STRUCTURE: BASIS FOR DESIGN OF ANTI-SARS DRUGS
2ZU2B:29-301; B:29-301COMPLEX STRUCTURE OF COV 229E 3CL PROTEASE WITH EPDTC
(-)
Porcine transmissible gastroenteritis coronavirus (strain Purdue) (TGEV) (1)
1LVOF:29-299; F:29-299; F:29-299; F:29-299; F:29-299; F:29-299STRUCTURE OF CORONAVIRUS MAIN PROTEINASE REVEALS COMBINATION OF A CHYMOTRYPSIN FOLD WITH AN EXTRA ALPHA-HELICAL DOMAIN
(-)
SARS coronavirus Sino1-11 (1)
2K7XA:187-306SOLUTION STRUCTURE OF C-TERMINAL DOMAIN OF SARS-COV MAIN PROTEASE
(-)
Family: Peptidase_C37 (1)
(-)
Chiba virus (strain GI/Human/Japan/Chiba 407/1987) (Hu/NLV/Chiba 407/1987/JP) (1)
1WQSD:1-169; D:1-169; D:1-169; D:1-169CRYSTAL STRUCTURE OF NOROVIRUS 3C-LIKE PROTEASE
(-)
Family: Peptidase_C4 (3)
(-)
Tobacco etch virus (TEV) (2)
1LVBB:8-221; B:8-221CATALYTICALLY INACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH SUBSTRATE
1LVME:230-232; E:230-232; E:230-232CATALYTICALLY ACTIVE TOBACCO ETCH VIRUS PROTEASE COMPLEXED WITH PRODUCT
(-)
Tobacco vein mottling virus (TVMV) (1)
3MMGB:3-216; B:3-216CRYSTAL STRUCTURE OF TOBACCO VEIN MOTTLING VIRUS PROTEASE
(-)
Family: Peptidase_S29 (32)
(-)
Hepatitis C virus (8)
2QV1B:1056-1204; B:1056-1204CRYSTAL STRUCTURE OF HCV NS3-4A V36M MUTANT
3KF2B:30-178; B:30-178THE HCV NS3/NS4A PROTEASE APO STRUCTURE
2XCFB:30-178; B:30-178CRYSTAL STRUCTURE OF HCV NS3 PROTEASE WITH A BORONATE INHIBITOR
2K1QA:30-178NMR STRUCTURE OF HEPATITIS C VIRUS NS3 SERINE PROTEASE COMPLEXED WITH THE NON-COVALENTLY BOUND PHENETHYLAMIDE INHIBITOR
3KEED:30-178; D:30-178; D:30-178; D:30-178HCV NS3/NS4A COMPLEXED WITH NON-COVALENT MACROCYCLIC COMPOUND TMC435
1RTLB:30-178; B:30-178CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN: NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND PYRROLIDINE-5,5-TRANSLACTAM INHIBITOR
2P59B:1056-1204; B:1056-1204CRYSTAL STRUCTURE OF HEPATITIS C VIRUS NS3.4A PROTEASE
2XCNB:30-178; B:30-178CRYSTAL STRUCTURE OF HCV NS3 PROTEASE WITH A BORONATE INHIBITOR
(-)
Hepatitis C virus genotype 1a (isolate H) (HCV) (3)
1N1LB:30-178; B:30-178CRYSTAL STRUCTURE OF HCV NS3 PROTEASE DOMAIN:NS4A PEPTIDE COMPLEX WITH COVALENTLY BOUND INHIBITOR (GW472467X)
1RGQB:33-181; B:33-181M9A HCV PROTEASE COMPLEX WITH PENTAPEPTIDE KETO-AMIDE INHIBITOR
2OINB:1056-1204; B:1056-1204CRYSTAL STRUCTURE OF HCV NS3-4A R155K MUNTANT
(-)
Hepatitis C virus genotype 1b (isolate BK) (HCV) (1)
1NS3B:30-178; B:30-178STRUCTURE OF HCV PROTEASE (BK STRAIN)
(-)
Hepatitis C virus genotype 1b (isolate Japanese) (HCV) (4)
1W3CB:30-176; B:30-176CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS3 PROTEASE IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
3OYPB:30-175; B:30-175HCV NS3/4A IN COMPLEX WITH LIGAND 3
3P8NB:30-178; B:30-178CRYSTAL STRUCTURE OF HCV NS3/NS4A PROTEASE COMPLEXED WITH BI 201335
3P8OB:30-178; B:30-178CRYSTAL STRUCTURE OF HCV NS3/NS4A PROTEASE COMPLEXED WITH DES-BROMINE ANALOGUE OF BI 201335
(-)
Hepatitis C virus subtype 1a (13)
3M5LA:1030-1178CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH ITMN-191
3M5MB:1030-1178; B:1030-1178AVOIDING DRUG RESISTANCE AGAINST HCV NS3/4A PROTEASE INHIBITORS
3M5ND:1030-1178; D:1030-1178; D:1030-1178; D:1030-1178CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH N-TERMINAL PRODUCT 4B5A
3M5OB:1030-1178; B:1030-1178CRYSTAL STRUCTURE OF HCV NS3/4A PROTEASE IN COMPLEX WITH N-TERMINAL PRODUCT 5A5B
3RC6A:1030-1178MOLECULAR MECHANISMS OF VIRAL AND HOST-CELL SUBSTRATE RECOGNITION BY HCV NS3/4A PROTEASE
2OBQC:30-178; C:30-178DISCOVERY OF THE HCV NS3/4A PROTEASE INHIBITOR SCH503034. KEY STEPS IN STRUCTURE-BASED OPTIMIZATION
2OC0C:30-178; C:30-178STRUCTURE OF NS3 COMPLEXED WITH A KETOAMIDE INHIBITOR SCH491762
2OC1C:30-178; C:30-178STRUCTURE OF THE HCV NS3/4A PROTEASE INHIBITOR CVS4819
2OC7C:30-178; C:30-178STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH571696
2OC8C:30-178; C:30-178STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A PEPTIDE AND KETOAMIDE SCH503034
3KNXC:30-178; C:30-178HCV NS3 PROTEASE DOMAIN WITH P1-P3 MACROCYCLIC KETOAMIDE INHIBITOR
3LONC:30-178; C:30-178HCV NS3-4A PROTEASE DOMAIN WITH KETOAMIDE INHIBITOR NARLAPREVIR
3LOXC:30-178; C:30-178HCV NS3-4A PROTEASE DOMAIN WITH A KETOAMIDE INHIBITOR DERIVATIVE OF BOCEPREVIR BOUND
(-)
Hepatitis C virus subtype 1b (3)
3O8CB:30-178; B:30-178VISUALIZING ATP-DEPENDENT RNA TRANSLOCATION BY THE NS3 HELICASE FROM HCV
3O8DB:30-178; B:30-178VISUALIZING ATP-DEPENDENT RNA TRANSLOCATION BY THE NS3 HELICASE FROM HCV
3O8RB:30-178; B:30-178VISUALIZING ATP-DEPENDENT RNA TRANSLOCATION BY THE NS3 HELICASE FROM HCV
(-)
Family: Peptidase_S3 (13)
(-)
Semliki forest virus (SFV) (2)
1VCPC:119-267; C:119-267; C:119-267SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM I)
1VCQB:119-267; B:119-267SEMLIKI FOREST VIRUS CAPSID PROTEIN (CRYSTAL FORM II)
(-)
Sindbis virus (SINV) (10)
1KXAA:107-264SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 106-264, TETRAGONAL CRYSTAL FORM
1KXBA:107-264SINDBIS VIRUS CAPSID (S215A MUTANT), TETRAGONAL CRYSTAL FORM
1KXCA:107-264SINDBIS VIRUS CAPSID (N190K MUTANT), TETRAGONAL CRYSTAL FORM
1KXDA:107-264SINDBIS VIRUS CAPSID (N222L MUTANT), TETRAGONAL CRYSTAL FORM
1KXEA:108-264SINDBIS VIRUS CAPSID (Y180S, E183G DOUBLE MUTANT), TETRAGONAL CRYSTAL FORM
1KXFA:107-264SINDBIS VIRUS CAPSID, (WILD-TYPE) RESIDUES 1-264, TETRAGONAL CRYSTAL FORM (FORM II)
1LD4D:6114-6264; D:6114-6264; D:6114-6264; D:6114-6264PLACEMENT OF THE STRUCTURAL PROTEINS IN SINDBIS VIRUS
1SVPB:107-265; B:107-265SINDBIS VIRUS CAPSID PROTEIN
1Z8YT:114-264; T:114-264; T:114-264; T:114-264MAPPING THE E2 GLYCOPROTEIN OF ALPHAVIRUSES
2SNWB:107-264; B:107-264SINDBIS VIRUS CAPSID PROTEIN, TYPE3 CRYSTAL FORM
(-)
Sindbis virus subtype Ockelbo (strain Edsbyn 82-5) (OCKV) (Ockelbo virus) (1)
1WYKD:114-264; D:114-264; D:114-264; D:114-264SINDBIS VIRUS CAPSID PROTEIN (114-264)
(-)
Family: Peptidase_S32 (2)
(-)
Equine arteritis virus (strain Bucyrus) (EAV) (2)
1MBMD:23-203; D:23-203; D:23-203; D:23-203NSP4 PROTEINASE FROM EQUINE ARTERITIS VIRUS
2L8KA:2-56NMR STRUCTURE OF THE ARTERIVIRUS NONSTRUCTURAL PROTEIN 7 ALPHA (NSP7 ALPHA)
(-)
Family: Peptidase_S39 (1)
(-)
Sesbania mosaic virus (1)
1ZYOA:158-314CRYSTAL STRUCTURE OF THE SERINE PROTEASE DOMAIN OF SESBANIA MOSAIC VIRUS POLYPROTEIN
(-)
Family: Peptidase_S6 (1)
(-)
Escherichia coli (1)
1WXRA:1-759CRYSTAL STRUCTURE OF HEME BINDING PROTEIN, AN AUTOTRANSPORTER HEMOGLOBINE PROTEASE FROM PATHOGENIC ESCHERICHIA COLI
(-)
Family: Peptidase_S7 (5)
(-)
Dengue virus 4 (1)
2VBCA:19-168CRYSTAL STRUCTURE OF THE NS3 PROTEASE-HELICASE FROM DENGUE VIRUS
(-)
Dengue virus type 1 (strain Nauru/West Pac/1974) (DENV-1) (1)
3L6PA:71-218CRYSTAL STRUCTURE OF DENGUE VIRUS 1 NS2B/NS3 PROTEASE
(-)
Dengue virus type 4 (strain Thailand/0348/1991) (DENV-4) (2)
2WHXA:21-168A SECOND CONFORMATION OF THE NS3 PROTEASE-HELICASE FROM DENGUE VIRUS
2WZQA:20-168INSERTION MUTANT E173GP174 OF THE NS3 PROTEASE-HELICASE FROM DENGUE VIRUS
(-)
Murray valley encephalitis virus (strain MVE-1-51) (MVEV) (1)
2WV9A:18-168CRYSTAL STRUCTURE OF THE NS3 PROTEASE-HELICASE FROM MURRAY VALLEY ENCEPHALITIS VIRUS
(-)
Family: Pico_P2A (1)
(-)
Coxsackievirus B4 (strain JVB / Benschoten / New York/51) (1)
1Z8RA:19-1452A CYSTEINE PROTEINASE FROM HUMAN COXSACKIEVIRUS B4 (STRAIN JVB / BENSCHOTEN / NEW YORK / 51)
(-)
Family: Trypsin (679)
(-)
Bacillus intermedius (2)
1P3CA:7-213GLUTAMYL ENDOPEPTIDASE FROM BACILLUS INTERMEDIUS
1P3EA:7-213STRUCTURE OF GLU ENDOPEPTIDASE IN COMPLEX WITH MPD
(-)
Bos taurus (Bovine) (190)
1K2I1:16-238CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN COMPLEX WITH 7-HYDROXYCOUMARIN
1MTNG:149-238; G:149-238; G:149-238; G:149-238BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION
1N8OC:149-238; C:149-238CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BOVINE CHYMOTRYPSIN AND ECOTIN
1P2MC:16-238; C:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2NC:16-238; C:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2OC:16-238; C:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2QC:16-238; C:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1T8LC:16-238; C:16-238CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8NC:16-238; C:16-238CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1T8OC:16-238; C:16-238CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1VGCC:151-238; C:151-238GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1YPHF:149-238; F:149-238; F:149-238; F:149-238HIGH RESOLUTION STRUCTURE OF BOVINE ALPHA-CHYMOTRYPSIN
2P8OC:151-238; C:151-238CRYSTAL STRUCTURE OF A BENZOHYDROXAMIC ACID/VANADATE COMPLEX BOUND TO CHYMOTRYPSIN A
2VGCC:151-238; C:151-238GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
2Y6TD:16-238; D:16-238; D:16-238; D:16-238MOLECULAR RECOGNITION OF CHYMOTRYPSIN BY THE SERINE PROTEASE INHIBITOR ECOTIN FROM YERSINIA PESTIS
3VGCC:151-238; C:151-238GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX
1KIGH:16-238BOVINE FACTOR XA
1MKWK:16-238; K:16-238THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1MKXK:16-238; K:16-238THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA-THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1TBQK:16-238; K:16-238CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
1TOCH:16-238; H:16-238; H:16-238; H:16-238STRUCTURE OF SERINE PROTEINASE
1UCYN:16-238; N:16-238; N:16-238; N:16-238THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
1UVTH:16-238BOVINE THROMBIN--BM14.1248 COMPLEX
1UVUH:16-237BOVINE THROMBIN--BM12.1700 COMPLEX
1VITH:16-238; H:16-238; H:16-238THROMBIN:HIRUDIN 51-65 COMPLEX
1YCPM:150-238; M:150-238; M:150-238THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
2ODYD:16-238; D:16-238THROMBIN-BOUND BOOPHILIN DISPLAYS A FUNCTIONAL AND ACCESSIBLE REACTIVE-SITE LOOP
1JIRA:16-238CRYSTAL STRUCTURE OF TRYPSIN COMPLEX WITH AMYLAMINE IN CYCLOHEXANE
1JRSA:16-238HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1JRTA:16-238HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1K1IA:16-238BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1JA:16-238BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1LA:16-238BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1MA:16-238BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1OA:16-238BOVINE TRYPSIN-INHIBITOR COMPLEX
1K1PA:16-238BOVINE TRYPSIN-INHIBITOR COMPLEX
1LQEA:16-238CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79.
1MAXA:16-238BETA-TRYPSIN PHOSPHONATE INHIBITED
1MAYA:16-238BETA-TRYPSIN PHOSPHONATE INHIBITED
1MTSA:16-238FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTUA:16-238FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTVA:16-238FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1MTWA:16-238FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1N6XA:16-238RIP-PHASING ON BOVINE TRYPSIN
1N6YA:16-238RIP-PHASING ON BOVINE TRYPSIN
1NTPA:16-238USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN
1O2IA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2JA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2LA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2MA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2NA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2OA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2PA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2QA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2RA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2SA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2TA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2UA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2WA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2XA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O2YA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O30A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O31A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O32A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O33A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O34A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O35A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O36A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O37A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O38A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O39A:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3BA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3DA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3EA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3FA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3GA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3HA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3IA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3JA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3KA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3LA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3MA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O3NA:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1OPHB:16-238NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN
1OX1A:16-238CRYSTAL STRUCTURE OF THE BOVINE TRYPSIN COMPLEX WITH A SYNTHETIC 11 PEPTIDE INHIBITOR
1OYQA:16-238TRYPSIN INHIBITOR COMPLEX
1P2IA:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2JA:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1P2KA:16-238STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON-COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1PPCE:16-238GEOMETRY OF BINDING OF THE BENZAMIDINE-AND ARGININE-BASED INHIBITORS N-ALPHA-(2-NAPHTHYL-SULPHONYL-GLYCYL)-DL-P-AMIDINOPHENYLALANYL-PIPERIDINE (NAPAP) AND (2R,4R)-4-METHYL-1-[N-ALPHA-(3-METHYL-1,2,3,4-TETRAHYDRO-8-QUINOLINESULPHONYL)-L-ARGINYL]-2-PIPERIDINE CARBOXYLIC ACID (MQPA) TO HUMAN ALPHA-THROMBIN: X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE NAPAP-TRYPSIN COMPLEX AND MODELING OF NAPAP-THROMBIN AND MQPA-THROMBIN
1PPEE:16-238THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I, A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES
1PPHE:16-238GEOMETRY OF BINDING OF THE NALPHA-TOSYLATED PIPERIDIDES OF M-AMIDINO-, P-AMIDINO-AND P-GUANIDINO PHENYLALANINE TO THROMBIN AND TRYPSIN: X-RAY CRYSTAL STRUCTURES OF THEIR TRYPSIN COMPLEXES AND MODELING OF THEIR THROMBIN COMPLEXES
1QA0A:7-222BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX
1QB1A:7-222BOVINE TRYPSIN WITH 1-[2-[5-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1-METHYL-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDIN-4-YL]PIPERIDINE-3-CARBOXYLIC ACID (ZK-806974)
1QB6A:7-222BOVINE TRYPSIN 3,3'-[3,5-DIFLUORO-4-METHYL-2, 6-PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK-805623) COMPLEX
1QB9A:7-222BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H-CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX
1QBNA:7-222BOVINE TRYPSIN 2-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6-[3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDINE-4-CARBOXYLIC ACID (ZK-806688) COMPLEX
1QBOA:7-222BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL-BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX
1QL8A:16-238FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1RXPA:16-238STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT-BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO-PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID
1S0QA:660-875NATIVE BOVINE PANCREATIC TRYPSIN
1S0RA:1-216BOVINE PANCREATIC TRYPSIN INHIBITED WITH BENZAMIDINE AT ATOMIC RESOLUTION
1SBWA:16-238CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION
1SFIA:16-238HIGH RESOLUTION STRUCTURE OF A POTENT, CYCLIC PROTEASE INHIBITOR FROM SUNFLOWER SEEDS
1SMFE:16-238STUDIES ON AN ARTIFICIAL TRYPSIN INHIBITOR PEPTIDE DERIVED FROM THE MUNG BEAN INHIBITOR
1TABE:16-238STRUCTURE OF THE TRYPSIN-BINDING DOMAIN OF BOWMAN-BIRK TYPE PROTEASE INHIBITOR AND ITS INTERACTION WITH TRYPSIN
1TAWA:16-238BOVINE TRYPSIN COMPLEXED TO APPI
1TGBA:16-238CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT, REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN
1TGCA:16-238ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1TGNA:17-238STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION
1TGSZ:16-238THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION, CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION
1TGTA:16-238ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1TIOA:16-238HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
1TNGA:16-238PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNHA:16-238PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNJA:16-238PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TNLA:16-238PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1TPAE:16-238THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPOA:16-238THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPPA:16-238THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1TPSA:16-238ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION
1TX7A:16-238BOVINE TRYPSIN COMPLEXED WITH P-AMIDINOPHENYLMETHYLPHOSPHINIC ACID (AMPA)
1TX8A:16-238BOVINE TRYPSIN COMPLEXED WITH AMSO
1TYNA:16-238ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS
1UTNA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTOA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTPA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTQA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1V2JT:16-238BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI) BT.C1
1V2KT:16-238FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D2
1V2LT:16-238BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D1
1V2MT:16-238BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.A1
1V2OT:16-238TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.B4
1V2PT:16-238TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.A4
1V2QT:16-238TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSWI)BT.B4
1V2RT:16-238TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)BT.B4
1V2ST:16-238BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.D1
1V2UT:16-238BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARINAT X(SSAI) BT.D1
1V2VT:16-238BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI) BT.C1
1XUFA:16-238TRYPSIN-BABIM-ZN+2, PH 8.2
1XUGA:16-238TRYPSIN-BABIM-ZN+2, PH 8.2
1XUHA:16-238TRYPSIN-KETO-BABIM-CO+2, PH 8.2
1XUIA:16-238TRYPSIN-KETO-BABIM, ZN+2-FREE, PH 8.2
1XUJA:16-238TRYPSIN-KETO-BABIM-ZN+2, PH 8.2
1XUKA:16-238TRYPSIN-BABIM-SULFATE, PH 5.9
1Y3UA:16-238TRYPSIN INHIBITOR COMPLEX
1Y3VA:16-238TRYPSIN INHIBITOR COMPLEX
1Y3WA:16-238TRYPSIN INHIBITOR COMPLEX
1Y3XA:16-238TRYPSIN INHIBITOR COMPLEX
1Y3YA:16-238TRYPSIN INHIBITOR COMPLEX
1Y59T:16-238DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1Y5AT:16-238DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1Y5BT:16-238DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1Y5UT:16-238DIANHYDROSUGAR-BASED BENZAMIDINE, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1YP9A:17-238TRYPSIN INHIBITOR COMPLEX
1YYY1:16-238TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1ZR0C:16-238; C:16-238CRYSTAL STRUCTURE OF KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR-2 WITH BOVINE TRYPSIN
1ZZZA:16-238TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
2O9QA:19-234THE CRYSTAL STRUCTURE OF BOVINE TRYPSIN COMPLEXED WITH A SMALL INHIBITION PEPTIDE ORB2K
2OXSA:16-238CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH BENZAMIDINE AT HIGH TEMPERATURE (35 C)
2PLXA:16-238TRYPSIN COMPLEXED TO A SYNTHETIC PEPTIDE FROM VERONICA HEDERIFOLIA
2PTCE:16-238THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2QN5T:19-238CRYSTAL STRUCTURE AND FUNCTIONAL STUDY OF THE BOWMAN-BIRK INHIBITOR FROM RICE BRAN IN COMPLEX WITH BOVINE TRYPSIN
2QYIC:316-538; C:316-538CRYSTAL STRUCTURE OF A BINARY COMPLEX BETWEEN AN ENGINEERED TRYPSIN INHIBITOR AND BOVINE TRYPSIN
2TGAA:16-238ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TGDA:17-238LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN, A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION
2TGTA:16-238ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2TIOA:16-238LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
2TPIZ:19-238ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2XTTB:16-238BOVINE TRYPSIN IN COMPLEX WITH EVOLUTIONARY ENHANCED SCHISTOCERCA GREGARIA PROTEASE INHIBITOR 1 (SGPI-1-P02)
2ZDKA:16-238EXPLORING TRYPSIN S3 POCKET
2ZDLA:16-238EXPLORING TRYPSIN S3 POCKET
2ZDMA:16-238EXPLORING TRYPSIN S3 POCKET
2ZDNA:16-238EXPLORING TRYPSIN S3 POCKET
2ZFSA:16-238EXPLORING TRYPSIN S3 POCKET
2ZHDA:16-238EXPLORING TRYPSIN S3 POCKET
2ZQ1A:16-238EXPLORING TRYPSIN S3 POCKET
3LJJA:16-238BOVINE TRYPSIN IN COMPLEX WITH UB-THR 10
3LJOA:16-238BOVINE TRYPSIN IN COMPLEX WITH UB-THR 11
3M7QA:1-216CRYSTAL STRUCTURE OF RECOMBINANT KUNITZ TYPE SERINE PROTEASE INHIBITOR-1 FROM THE CARIBBEAN SEA ANEMONE STICHODACTYLA HELIANTHUS IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN
3MFJA:16-238BOVINE TRYPSIN AT 0.8 A RESOLUTION, RESTRAINED REFINEMENT
3MI4A:16-238BOVINE TRYPSIN AT 0.8 A RESOLUTION, NON-RESTRAINED REFINEMENT
3NK8A:16-238TRYPSIN IN COMPLEX WITH FLUORINE-CONTAINING FRAGMENT
3NKKA:16-238TRYPSIN IN COMPLEX WITH FLUORINE CONTAINING FRAGMENT
3OTJE:16-238A CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BPTI (BOVINE PANCREATIC TRYPSIN INHIBITOR) BY X-RAY/NEUTRON JOINT REFINEMENT
3PTBA:16-238THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
3PTNA:16-238ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
3QK1A:16-238CRYSTAL STRUCTURE OF ENTEROKINASE-LIKE TRYPSIN VARIANT
3RDZB:19-234; B:19-234CRYSTAL STRUCTURE OF RBTI-TRYPSIN COMPLEX AT 2.26 ANGSTROM RESOLUTION
3TPIZ:16-238THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN, TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
(-)
Drosophila melanogaster (Fruit fly) (1)
2XXLB:119-368; B:119-368CRYSTAL STRUCTURE OF DROSOPHILA GRASS CLIP SERINE PROTEASE OF TOLL PATHWAY
(-)
Escherichia coli (strain K12) (13)
2QF3C:50-245; C:50-245; C:50-245STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2QGRA:50-245STRUCTURE OF THE R178A MUTANT OF DELTA PDZ DEGS PROTEASE
2R3UC:50-245; C:50-245; C:50-245CRYSTAL STRUCTURE OF THE PDZ DELETION MUTANT OF DEGS
2R3YC:50-245; C:50-245; C:50-245CRYSTAL STRUCTURE OF THE DEGS PROTEASE IN COMPLEX WITH THE YWF ACTIVATING PEPTIDE
2RCEI:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245DFP MODIFIED DEGS DELTA PDZ
3LGIC:50-245; C:50-245; C:50-245STRUCTURE OF THE PROTEASE DOMAIN OF DEGS (DEGS-DELTAPDZ) AT 1.65 A
3LGTA:50-245Y162A/H198P DOUBLE MUTANT OF DEGS-DELTAPDZ PROTEASE
3LGUA:50-245Y162A MUTANT OF THE DEGS-DELTAPDZ PROTEASE
3LGVI:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
3LGWA:50-245H198P/T167V DOUBLE MUTANT OF DEGS-DELTAPDZ PROTEASE
3LGYA:50-245R178A MUTANT OF THE DEGS-DELTAPDZ PROTEASE
3LH1A:50-245Q191A MUTANT OF THE DEGS-DELTAPDZ
3LH3I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245; I:50-245DFP MODIFIED DEGS DELTA PDZ
(-)
Escherichia coli O157:H7 (4)
1SOTC:50-245; C:50-245; C:50-245CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
1SOZC:50-245; C:50-245; C:50-245CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
1TE0B:50-245; B:50-245STRUCTURAL ANALYSIS OF DEGS, A STRESS SENSOR OF THE BACTERIAL PERIPLASM
1VCWC:50-245; C:50-245; C:50-245CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
(-)
Fusarium oxysporum (Panama disease fungus) (8)
1PPZA:16-235TRYPSIN COMPLEXES AT ATOMIC AND ULTRA-HIGH RESOLUTION
1PQ5A:16-235TRYPSIN AT PH 5, 0.85 A
1PQ7A:16-235TRYPSIN AT 0.8 A, PH5 / BORAX
1PQ8A:16-235TRYPSIN AT PH 4 AT ATOMIC RESOLUTION
1PQAA:16-235TRYPSIN WITH PMSF AT ATOMIC RESOLUTION
1XVMA:16-235TRYPSIN FROM FUSARIUM OXYSPORUM- ROOM TEMPERATURE TO ATOMIC RESOLUTION
1XVOA:16-235TRYPSIN FROM FUSARIUM OXYSPORUM AT PH 6
2VU8E:16-238CRYSTAL STRUCTURE OF AN INSECT INHIBITOR WITH A FUNGAL TRYPSIN
(-)
Holotrichia diomphalia (Korean black chafer) (1)
2OLGA:110-359CRYSTAL STRUCTURE OF THE SERINE PROTEASE DOMAIN OF PROPHENOLOXIDASE ACTIVATING FACTOR-I IN A ZYMOGEN FORM
(-)
Homo sapiens (Human) (339)
1MD7A:447-680MONOMERIC STRUCTURE OF THE ZYMOGEN OF COMPLEMENT PROTEASE C1R
1MD8A:447-680MONOMERIC STRUCTURE OF THE ACTIVE CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
2QY0D:447-680; D:447-680ACTIVE DIMERIC STRUCTURE OF THE CATALYTIC DOMAIN OF C1R REVEALS ENZYME-PRODUCT LIKE CONTACTS
1KYNB:316-538; B:316-538CATHEPSIN-G
1T32A:16-238A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
1RRKA:456-727CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B
1RS0A:456-727CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH DI-ISOPROPYL-PHOSPHATE (DIP)
1RTKA:456-727CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH 4-GUANIDINOBENZOIC ACID
2OK5A:456-727HUMAN COMPLEMENT FACTOR B
2WINL:456-727; L:456-727; L:456-727; L:456-727C3 CONVERTASE (C3BBB) STABILIZED BY SCIN
2XWBH:456-727; H:456-727; J:1-223; J:1-223CRYSTAL STRUCTURE OF COMPLEMENT C3B IN COMPLEX WITH FACTORS B AND D
2XWJL:456-727; L:456-727; L:456-727; L:456-727CRYSTAL STRUCTURE OF COMPLEMENT C3B IN COMPLEX WITH FACTOR B
2XW9A:1-223CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT S183A
2XWAB:1-223; B:1-223CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A
1KLTA:16-238CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION
1PJPA:16-238THE 2.2 A CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SUCCINYL-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
1T31A:16-238A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
3N7OA:16-238X-RAY STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR.
2ODPA:446-686COMPLEMENT COMPONENT C2A, THE CATALYTIC FRAGMENT OF C3- AND C5-CONVERTASE OF HUMAN COMPLEMENT
2ODQA:446-686COMPLEMENT COMPONENT C2A, THE CATALYTIC FRAGMENT OF C3- AND C5-CONVERTASE OF HUMAN COMPLEMENT
1PPFE:16-238X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR
1PPGE:16-238THE REFINED 2.3 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE ELASTASE IN A COMPLEX WITH A VALINE CHLOROMETHYL KETONE INHIBITOR
2RG3A:16-238COVALENT COMPLEX STRUCTURE OF ELASTASE
3Q76B:16-238; B:16-238STRUCTURE OF HUMAN NEUTROPHIL ELASTASE (UNCOMPLEXED)
3Q77A:16-238STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
1LPGB:16-238CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
1LPKB:16-238CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
1LPZB:16-238CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1LQDB:16-238CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1MQ5A:16-238CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL) AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1NFUA:16-238CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747
1NFWA:16-238CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685
1NFXA:16-238CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944
1NFYA:16-238CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095
1P0SH:16-238CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEX WITH ECOTIN M84R
1V3XA:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL] CARBONYL-2-CARBAMOYL-4-(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE
1WU1A:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2-YL]CARBONYL]PIPERAZINE
1XKAC:16-238FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1XKBD:16-238; D:16-238FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A,(2S)-(3'-AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1Z6EA:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3'-AMINO-1,2-BENZISOXAZOL-5'-YL)-N-(4-(2'-((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389)
2JKHA:16-238FACTOR XA - CATION INHIBITOR COMPLEX
2P16A:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS-562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1-PIPERIDINYL)PHENYL)-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3, 4-C]PYRIDINE-3-CARBOXAMIDE
2P3UB:16-238CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3-CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL-2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663}
2P93A:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE
2P95A:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R,2S)-2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE
2PR3A:16-238FACTOR XA INHIBITOR
2Q1JA:16-238THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS
2RA0A:16-238X-RAY STRUCTURE OF FXA IN COMPLEX WITH 7-FLUOROINDAZOLE
2UWLA:16-238SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWOA:16-238SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
2UWPA:16-238FACTOR XA INHIBITOR COMPLEX
2VH0A:16-238STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS
2VH6A:16-238STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS
2VVCB:16-238; B:16-238AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVUA:16-238AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VVVA:16-238AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
2VWLA:16-238AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWMB:16-238; B:16-238AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWNA:16-238AMINOPYRROLIDINE FACTOR XA INHIBITOR
2VWOA:16-238AMINOPYRROLIDINE FACTOR XA INHIBITOR
2W26A:16-238FACTOR XA IN COMPLEX WITH BAY59-7939
2W3IA:16-238CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 2
2W3KA:16-238CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 4,4-DISUBSTITUTED PYRROLIDINE-1,2-DICARBOXAMIDE INHIBITOR 1
2XBVA:16-238FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBWA:16-238FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBXA:16-238FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XBYA:16-238FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC0A:16-238FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2XC4A:16-238FACTOR XA IN COMPLEX WITH A PYRROLIDINE-3,4-DICARBOXYLIC ACID INHIBITOR
2Y7XA:16-238THE DISCOVERY OF POTENT AND LONG-ACTING ORAL FACTOR XA INHIBITORS WITH TETRAHYDROISOQUINOLINE AND BENZAZEPINE P4 MOTIFS
2Y7ZA:16-238STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
2Y80A:16-238STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
2Y81A:16-238STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
2Y82A:16-238STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
3K9XD:16-238; D:16-238X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2-METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
3KL6A:16-238DISCOVERY OF TETRAHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVE TAK-442: A POTENT, SELECTIVE AND ORALLY ACTIVE FACTOR XA INHIBITOR
3KQBA:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2'-(METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE
3KQCA:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2'- (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-4,5-DIHYDRO-1H- 1,2,4-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-5,6- DIHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQDA:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-4,5- DIHYDRO-1H-1, 2,4-TRIAZOL-3-YL)PHENYL)-6-(2'-(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-5,6-DIHYDRO- 1H-PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3KQEA:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-4,5-DIHYDRO-1H-1,2,4-TRIAZOL-3-YL)PHENYL)-6-(2'- (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-5,6-DIHYDRO-1H- PYRAZOLO[3,4-C]PYRIDIN-7(4H)-ONE
3LIWA:16-238FACTOR XA IN COMPLEX WITH (R)-2-(1-ADAMANTYLCARBAMOYLAMINO)-3-(3-CARBAMIDOYL-PHENYL)-N-PHENETHYL-PROPIONIC ACID AMIDE
3M37A:16-238FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[2-(AMINOMETHYL) PHENYL]-N-(3-FLUORO-2'-SULFAMOYLBIPHENYL-4-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC602)
1XX9B:16-238; B:16-238CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTINM84R
1XXDB:16-238; B:16-238CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH MUTATED ECOTIN
1XXFB:16-238; B:16-238CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTIN MUTANT (ECOTINP)
1ZHMA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE COAGULATION FACTOR XIA IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K437 MUTANT)
1ZHPA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K505 MUTANT)
1ZHRA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-C482S-K437A MUTANT)
1ZJDA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH KUNITZ PROTEASE INHIBITOR DOMAIN OF PROTEASE NEXIN II
1ZLRA:16-238FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH 2-GUANIDINO-1-(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)ETHYL NICOTINATE
1ZMJA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH 4-(GUANIDINOMETHYL)-PHENYLBORONIC ACID
1ZMLA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3,2-DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE
1ZMNA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-1,3, 2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE
1ZOMA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
1ZPBA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 4-METHYL-PENTANOIC ACID {1-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL-PROPYL}-AMIDE
1ZPCA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-[2-(3-CHLORO-PHENYL)-2-HYDROXY-ACETYLAMINO]-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-3-METHYL-BUTYRAMIDE
1ZRKA:16-238FACTOR XI COMPLEXED WITH 3-HYDROXYPROPYL 3-(7-AMIDINONAPHTHALENE-1-CARBOXAMIDO)BENZENESULFONATE
1ZSJA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-(7-CARBAMIMIDOYL-NAPHTHALEN-1-YL)-3-HYDROXY-2-METHYL-BENZAMIDE
1ZSLA:16-238FACTOR XI COMPLEXED WITH A PYRIMIDINONE INHIBITOR
1ZTKA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-AMINO-6-OXO-2-M-TOLYL-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE
1ZTLA:16-238CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]-2-{6-OXO-5-[(QUINOLIN-8-YLMETHYL)-AMINO]-2-M-TOLYL-6H-PYRIMIDIN-1-YL}-ACETAMIDE
1JBUH:20-238COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183
1KLIH:16-238COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA
1KLJH:16-238CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA
1O5DH:16-238DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1QFKH:153-387STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION
1W0YH:16-238TF7A_3771 COMPLEX
1W7XH:16-238FACTOR7 - 413 COMPLEX
1W8BH:16-238FACTOR7 - 413 COMPLEX
1WQVH:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D-THR-MET-P-AMINOBENZAMIDINE
1WSSH:16-238HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
1WTGH:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
1WUNH:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
1WV7H:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
1YGCH:16-238SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR
1Z6JH:16-238CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
2PUQH:153-387CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
2ZP0H:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D-ILE-GLN-P-AMINOBENZAMIDINE
2ZWLH:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
2ZZUH:16-238HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-(3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
1RFNA:16-238HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE
2WPHS:16-238FACTOR IXA SUPERACTIVE TRIPLE MUTANT
2WPIS:16-238FACTOR IXA SUPERACTIVE DOUBLE MUTANT
2WPJS:16-238FACTOR IXA SUPERACTIVE TRIPLE MUTANT, NACL-SOAKED
2WPKS:16-238FACTOR IXA SUPERACTIVE TRIPLE MUTANT, ETHYLENE GLYCOL-SOAKED
2WPLS:16-238FACTOR IXA SUPERACTIVE TRIPLE MUTANT, EDTA-SOAKED
2WPMS:16-238FACTOR IXA SUPERACTIVE MUTANT, EGR-CMK INHIBITED
3KCGH:16-238CRYSTAL STRUCTURE OF THE ANTITHROMBIN-FACTOR IXA-PENTASACCHARIDE COMPLEX
3LC5A:16-238SELECTIVE BENZOTHIOPHINE INHIBITORS OF FACTOR IXA
1OP8F:16-238; F:16-238; F:16-238; F:16-238; F:16-238; F:16-238CRYSTAL STRUCTURE OF HUMAN GRANZYME A
1MZAA:16-238CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
1MZDA:16-238CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
2ZGCA:1-224CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME M
2ZGHA:1-224CRYSTAL STRUCTURE OF ACTIVE GRANZYME M BOUND TO ITS PRODUCT
2ZGJA:1-224CRYSTAL STRUCTURE OF D86N-GZMM COMPLEXED WITH ITS OPTIMAL SYNTHESIZED SUBSTRATE
2ZKSA:1-224STRUCTURAL INSIGHTS INTO THE PROTEOLYTIC MACHINERY OF APOPTOSIS-INDUCING GRANZYME M
1O5EH:16-238DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5FH:16-238DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1P57B:16-238EXTRACELLULAR DOMAIN OF HUMAN HEPSIN
1Z8GA:163-400CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE TRANSMEMBRANE SERINE PROTEASE HEPSIN WITH COVALENTLY BOUND PREFERRED SUBSTRATE.
1YBWB:408-641; B:408-641PROTEASE DOMAIN OF HGFA WITH NO INHIBITOR
1YC0A:408-641SHORT FORM HGFA WITH FIRST KUNITZ DOMAIN FROM HAI-1
2R0KA:16-238PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58
2R0LA:16-238SHORT FORM HGFA WITH INHIBITORY FAB75
2WUBC:16-238; C:16-238CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
3K2UA:16-238CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40
1SI5H:495-716PROTEASE-LIKE DOMAIN FROM 2-CHAIN HEPATOCYTE GROWTH FACTOR
1SPJA:16-238STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE
2ZCHP:16-238CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
2ZCKP:16-239CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA, A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY
2PSXA:16-238CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN
2PSYA:16-238CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN AND ZINC
1L2EA:16-238HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR
1LO6A:16-238HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR AT 1.56 A RESOLUTION
2QXGB:16-238; B:16-238CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH ALA-ALA-PHE-CHLOROMETHYLKETONE
2QXHA:16-238CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2QXIA:16-238HIGH RESOLUTION STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2QXJA:16-238CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE AND COPPER
1Q3XB:445-679; B:445-679CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-2
1ZJKA:445-679CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC REGION OF HUMAN MASP-2
1L4DA:562-784CRYSTAL STRUCTURE OF MICROPLASMINOGEN-STREPTOKINASE ALPHA DOMAIN COMPLEX
1L4ZA:562-784X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF MICROPLASMINOGEN WITH ALPHA DOMAIN OF STREPTOKINASE IN THE PRESENCE CADMIUM IONS
1QRZD:562-784; D:562-784; D:562-784; D:562-784CATALYTIC DOMAIN OF PLASMINOGEN
1RJXB:562-784HUMAN PLASMINOGEN CATALYTIC DOMAIN, K698M MUTANT
3L3TD:16-238; D:16-238; D:16-238; D:16-238HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT (APPIR15K)
3NCLA:11-252CRYSTAL STRUCTURE OF MT-SP1 BOUND TO BENZAMIDINE PHOSPHONATE INHIBITOR
3NPSA:16-238CRYSTAL STRUCTURE OF MEMBRANE-TYPE SERINE PROTEASE 1 (MT-SP1) IN COMPLEX WITH THE FAB INHIBITOR S4
1JMOH:16-238CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II-S195A THROMBIN COMPLEX
1JOUF:16-238; F:16-238; F:16-238CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
1K21H:16-238HUMAN THROMBIN-INHIBITOR COMPLEX
1K22H:16-238HUMAN THROMBIN-INHIBITOR COMPLEX
1KTSB:16-238THROMBIN INHIBITOR COMPLEX
1KTTB:16-238THROMBIN INHIBITOR COMPLEX
1LHCH:16-238HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH
1LHDH:16-238HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH
1LHEH:16-238HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N-BUTYL-AMIDINO-GLYCINE-OH
1LHFH:16-238HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-HOMOLYS-OH
1LHGH:16-238HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROORNITHINE-OH
1MH0B:16-238; B:16-238CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
1MU6B:16-238CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378,622
1MU8B:16-238THROMBIN-HIRUGEN_L-378,650
1MUEB:16-238THROMBIN-HIRUGEN-L405,426
1NM6A:16-238THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR AT 1.8A
1NO9H:16-238DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES.
1NRNH:16-238CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NROH:16-238CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRPH:16-238CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRQH:16-238CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRRH:16-238CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NRSH:16-238CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1NT1A:16-238THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR
1NU7F:16-238; F:16-238STAPHYLOCOAGULASE-THROMBIN COMPLEX
1NU9D:16-238; D:16-238STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX
1NY22:16-238HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN
1O0DH:16-238HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO-ARG-TYPE INHIBITOR AND A C-TERMINAL HIRUDIN DERIVED EXO-SITE INHIBITOR
1O2GH:16-238ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1O5GH:16-238DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1OOKB:16-238CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND HUMAN ALPHA-THROMBIN
1OYTH:16-238COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR
1P8VC:1-250CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A
1PPBH:16-238THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
1QBVH:16-238CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR
1QHRB:16-238NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ1B:16-238NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QJ6B:16-238NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
1QURH:16-238HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT, BENZAMIDINE-BASED SYNTHETIC INHIBITOR
1RD3D:16-238; D:16-2382.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1RIWC:185-280; C:185-280THROMBIN IN COMPLEX WITH NATURAL PRODUCT INHIBITOR OSCILLARIN
1SFQE:16-238; E:16-238FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
1SG8E:16-238; E:16-238CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
1SHHE:16-238; E:16-238SLOW FORM OF THROMBIN BOUND WITH PPACK
1SL3A:16-238CRYSTAL STRUCTUE OF THROMBIN IN COMPLEX WITH A POTENT P1 HETEROCYCLE-ARYL BASED INHIBITOR
1SR5C:16-238ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE
1T4VH:37-280CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1TA2A:16-238CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 1
1TA6A:16-238CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 14B
1TBZH:16-238HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5-(AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L-PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
1THPB:16-238STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
1THRH:16-238STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1THSH:16-238STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
1TMTH:16-238CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TMUH:16-238CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
1TOMH:16-238ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1TQ0D:16-238; D:16-238CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1TQ7B:16-238CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANT W215A/E217A BOUND TO PPACK
1TWXB:16-238CRYSTAL STRUCTURE OF THE THROMBIN MUTANT D221A/D222K
1UMAH:16-238ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(N,N-DIMETHYLCARBAMOYL)-ALPHA-AZALYSINE
1UVSH:16-238BOVINE THROMBIN--BM51.1011 COMPLEX
1VR1H:16-238SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR-1
1VZQH:16-238COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165
1W7GH:16-238ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L-ARGININE TEMPLATE INHIBITOR CS107
1WAYB:16-238ACTIVE SITE THROMBIN INHIBITORS
1WBGB:16-238ACTIVE SITE THROMBIN INHIBITORS
1XM1A:16-238NONBASIC THROMBIN INHIBITOR COMPLEX
1XMNH:16-238; H:16-238; H:16-238; H:16-238CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
1YPEH:16-238THROMBIN INHIBITOR COMPLEX
1YPGH:16-238THROMBIN INHIBITOR COMPLEX
1YPJH:16-238THROMBIN INHIBITOR COMPLEX
1YPKH:16-238THROMBIN INHIBITOR COMPLEX
1YPLH:16-238X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1008
1YPMH:16-238X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1014
1Z71A:16-238THROMBIN AND P2 PYRIDINE N-OXIDE INHIBITOR COMPLEX STRUCTURE
1Z8IB:16-238CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193A BOUND TO PPACK
1Z8JB:16-238CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193P BOUND TO PPACK
1ZGIA:16-238THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 21
1ZGVA:16-238THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 2
1ZRBA:16-238THROMBIN IN COMPLEX WITH AN AZAFLUORENYL INHIBITOR 23B
2JH0D:16-238HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JH5D:16-238HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2JH6D:16-238HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
2OD3B:16-238HUMAN THROMBIN CHIMERA WITH HUMAN RESIDUES 184A, 186, 186A, 186B, 186C AND 222 REPLACED BY MURINE THROMBIN EQUIVALENTS.
2PGBB:16-238INHIBITOR-FREE HUMAN THROMBIN MUTANT C191A-C220A
2PGQB:16-238HUMAN THROMBIN MUTANT C191A-C220A IN COMPLEX WITH THE INHIBITOR PPACK
2PKSC:185-280; C:185-280THROMBIN IN COMPLEX WITH INHIBITOR
2PW8H:16-238CRYSTAL STRUCTURE OF SULFO-HIRUDIN COMPLEXED TO THROMBIN
2R2MB:37-2802-(2-CHLORO-6-FLUOROPHENYL)ACETAMIDES AS POTENT THROMBIN INHIBITORS
2THFB:16-238STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG-CHLOROMETHYLKETONE
2UUFB:16-238THROMBIN-HIRUGEN BINARY COMPLEX AT 1.26A RESOLUTION
2UUKB:16-238THROMBIN-HIRUGEN-GW420128 TERNARY COMPLEX AT 1.39A RESOLUTION
2V3HH:16-238THROMBIN WITH 3-CYCLE NO F
2V3OH:16-238THROMBIN WITH 3-CYCLE WITH F
2ZC9H:16-238THROMBIN IN COMPLEX WITH INHIBITOR
2ZDVH:16-238EXPLORING THROMBIN S1 POCKET
2ZF0H:16-238EXPLORING THROMBIN S1 POCKET
2ZFFH:16-238EXPLORING THROMBIN S1-POCKET
2ZFPH:16-238THROMBIN INIBITION
2ZFQH:16-238EXPLORING THROMBIN S3 POCKET
2ZFRH:16-238EXPLORING THROMBIN S3 POCKET
2ZG0H:16-238EXPLORING THROMBIN S3 POCKET
2ZGBH:16-238THROMBIN INHIBITION
2ZGXH:16-238THROMBIN INHIBITION
2ZHEH:16-238EXPLORING THROMBIN S3 POCKET
2ZHFH:16-238EXPLORING THROMBIN S3 POCKET
2ZHQH:16-238THROMBIN INHIBITION
2ZHWH:16-238EXPLORING THROMBIN S3 POCKET
2ZI2H:16-238THROMBIN INHIBITION
2ZIQH:16-238THROMBIN INHIBITION
2ZNKH:16-238THROMBIN INHIBITION
2ZO3H:16-238BISPHENYLIC THROMBIN INHIBITORS
3JZ1B:16-238CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E:NA+ FORM
3JZ2B:16-238CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E* FORM
3K65B:321-570CRYSTAL STRUCTURE OF PRETHOMBIN-2/FRAGMENT-2 COMPLEX
3LU9E:16-238; E:16-238CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT S195A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
3NXPA:416-638CRYSTAL STRUCTURE OF HUMAN PRETHROMBIN-1
3P6ZH:364-613; H:364-613STRUCTURAL BASIS OF THROMBIN MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
3PMHB:16-238MECHANISM OF SULFOTYROSINE-MEDIATED GLYCOPROTEIN IB INTERACTION WITH TWO DISTINCT ALPHA-THROMBIN SITES
3QDZD:16-238; D:16-238CRYSTAL STRUCTURE OF THE HUMAN THROMBIN MUTANT D102N IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR4.
3QGNB:16-238THE ALLOSTERIC E*-E EQUILIBRIUM IS A KEY PROPERTY OF THE TRYPSIN FOLD
3R3GB:16-238STRUCTURE OF HUMAN THROMBIN WITH RESIDUES 145-150 OF MURINE THROMBIN.
3S7HB:16-238STRUCTURE OF THROMBIN MUTANT Y225P IN THE E* FORM
3S7KD:16-238; D:16-238STRUCTURE OF THROMBIN MUTANT Y225P IN THE E FORM
2OQ5A:16-238CRYSTAL STRUCTURE OF DESC1, A NEW MEMBER OF THE TYPE II TRANSMEMBRANE SERINE PROTEINASES FAMILY
1RTFB:16-238COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA]
1TRNB:16-238; B:16-238CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151
2RA3B:16-238; B:16-238HUMAN CATIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2R9PD:16-238; D:16-238; D:16-238; D:16-238HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
3L33D:16-238; D:16-238; D:16-238; D:16-238HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR(APPI)
2ZEBD:1-237; D:1-237; D:1-237; D:1-237POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
2ZECD:16-252; D:16-252; D:16-252; D:16-252POTENT, NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
2ZA5D:16-252; D:16-252; D:16-252; D:16-252CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
1LMWD:16-238; D:16-238LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
1O5BB:16-238DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1O5CB:16-238DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
1OWDA:1-240SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWEA:1-254SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWHA:1-254SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWIA:1-240SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWJA:1-240SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1OWKA:1-240SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SC8U:16-238UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-J435 COMPLEX
1SQAA:1-254SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SQOA:1-254SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1SQTA:1-240SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
1U6QA:1-240SUBSTITUTED 2-NAPHTHAMADINE INHIBITORS OF UROKINASE
1VJ9U:16-238UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT464 COMPLEX
1VJAU:16-238UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT463 COMPLEX
1W0ZU:16-238UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W10U:16-238UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W11U:16-238UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W12U:16-238UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W13U:16-238UROKINASE TYPE PLASMINOGEN ACTIVATOR
1W14U:16-238UROKINASE TYPE PLASMINOGEN ACTIVATOR
2NWNA:16-238NEW PHARMACOPHORE FOR SERINE PROTEASE INHIBITION REVEALED BY CRYSTAL STRUCTURE OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR COMPLEXED WITH A CYCLIC PEPTIDYL INHIBITOR, UPAIN-1
2O8TA:16-238CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q) IN COMPLEX WITH INHIBITORS
2O8UA:16-238CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
2O8WA:16-238CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
2R2WU:16-238UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-GPPE COMPLEX
2VINA:16-238FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIOA:16-238FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIPA:16-238FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIQA:16-238FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIVA:16-238FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VIWA:16-238FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2VNTF:10-250; F:10-250; F:10-250; F:10-250; F:10-250; F:10-250UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
3KHVA:16-238CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4-(AMINOMETHYL-PHENYL)-METHANOL
3KIDU:16-238THE CRYSTAL STRUCTURES OF 2-AMINOBENZOTHIAZOLE-BASED INHIBITORS IN COMPLEXES WITH UROKINASE-TYPE PLASMINOGEN ACTIVATOR
3M61U:16-238CRYSTAL STRUCTURE OF COMPLEX OF UROKINASE AND A UPAIN-1 VARIANT(W3A) IN PH4.6 CONDITION
3MHWU:16-238THE COMPLEX CRYSTAL STRUCTURE OF UROKIANSE AND 2-AMINOBENZOTHIAZOLE
3MWIU:16-238THE COMPLEX CRYSTAL STRUCTURE OF UROKIANSE AND 5-NITRO-1H-INDOLE-2-AMIDINE
(-)
Lysobacter enzymogenes (16)
1P01A:16-226SERINE PROTEASE MECHANISM. STRUCTURE OF AN INHIBITORY COMPLEX OF ALPHA-LYTIC PROTEASE AND A TIGHTLY BOUND PEPTIDE BORONIC ACID
1P02A:16-226STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P03A:16-226STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P04A:16-226STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
1P09A:16-226STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
1P10A:16-226STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
1P11E:16-226CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
1P12E:16-226CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
1QRWA:3-179CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS, R102H/G134S, PH 8
1SSXA:16-2260.83A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE AT PH 8
1TALA:16-226ALPHA-LYTIC PROTEASE AT 120 K (SINGLE STRUCTURE MODEL)
2LPRA:16-226STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
3LPRA:16-226STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
3M7TA:3-179CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE SB2+3 E8A/R105S MUTANT
3M7UA:3-179CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE SB1+2 R64A/E182Q MUTANT
3PROB:3-179; B:3-179ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION
(-)
Mesocricetus auratus (Golden hamster) (1)
2RDLB:16-238; B:16-238HAMSTER CHYMASE 2
(-)
Mus musculus (Mouse) (4)
1SGFZ:16-238; Z:16-238; X:26-238; X:26-238CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
1NPMB:16-238; B:16-238NEUROPSIN, A SERINE PROTEASE EXPRESSED IN THE LIMBIC SYSTEM OF MOUSE BRAIN
2OCVB:16-238STRUCTURAL BASIS OF NA+ ACTIVATION MIMICRY IN MURINE THROMBIN
2PV9B:16-238CRYSTAL STRUCTURE OF MURINE THROMBIN IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF MURINE PAR4
(-)
Oncorhynchus keta (Chum salmon) (3)
2ZPRB:1-215; B:1-215CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 2 FROM CHUM SALMON
2ZPSA:1-215CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 3 FROM CHUM SALMON
2ZPQB:1-215; B:1-215CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 1 FROM CHUM SALMON
(-)
Rattus norvegicus (Rat) (15)
1KDQB:151-238; B:151-238CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT S189D RAT CHYMOTRYPSIN
1TONA:16-238RAT SUBMAXILLARY GLAND SERINE PROTEASE, TONIN. STRUCTURE SOLUTION AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION
3RP2B:16-238; B:16-238THE STRUCTURE OF RAT MAST CELL PROTEASE II AT 1.9-ANGSTROMS RESOLUTION
1K9OE:16-238CRYSTAL STRUCTURE OF MICHAELIS SERPIN-TRYPSIN COMPLEX
1SLUB:16-238RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN
1SLVB:16-238RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; COPPER-BOUND
1SLWB:16-238RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; NICKEL-BOUND
1SLXB:16-238RAT ANIONIC N143H, E151H TRYPSIN COMPLEXED TO A86H ECOTIN; ZINC-BOUND
1TRMB:16-238; B:16-238THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
1YKTA:16-238TRYPSIN/BPTI COMPLEX MUTANT
1YLCA:16-238TRYPSIN/BPTI COMPLEX MUTANT
1YLDA:16-238TRYPSIN/BPTI COMPLEX MUTANT
2TRMA:16-238THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
3TGIE:16-238WILD-TYPE RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
3TGJE:16-238S195A TRYPSINOGEN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
(-)
Salmo salar (Atlantic salmon) (7)
1UTJA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTKA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTLM:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1UTMA:16-238TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS, X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2STAE:16-238ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA MAXIMA TRYPSIN INHIBITOR I)
2STBE:16-238ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
2TBSA:16-238COLD-ADAPTION OF ENZYMES: STRUCTURAL COMPARISON BETWEEN SALMON AND BOVINE TRYPSINS
(-)
Staphylococcus aureus (1)
1QTFA:28-223CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
(-)
Staphylococcus aureus (strain NCTC 8325) (3)
2W7SD:3-194; D:3-194; D:3-194; D:3-194SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (1.8A)
2W7UD:3-194; D:3-194; D:3-194; D:3-194SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (2.4A)
2VIDB:2-198; B:2-198SERINE PROTEASE SPLB FROM STAPHYLOCOCCUS AUREUS AT 1.8A RESOLUTION
(-)
Streptomyces griseus (24)
1SGCA:65-236THE 1.8 ANGSTROMS STRUCTURE OF THE COMPLEX BETWEEN CHYMOSTATIN AND STREPTOMYCES GRISEUS PROTEASE A. A MODEL FOR SERINE PROTEASE CATALYTIC TETRAHEDRAL INTERMEDIATES
3SGAE:65-236STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
1SGDE:16-236ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
1SGNE:16-236ASN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
1SGPE:16-236ALA 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
1SGRE:16-236LEU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
1SGYE:16-236TYR 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
2NU0E:16-236MOLECULAR STRUCTURES OF THE COMPLEXES OF SGPB WITH OMTKY3 AROMATIC P1 VARIANTS TRP18I, HIS18I, PHE18I, AND TYR18I
2NU1E:16-236MOLECULAR STRUCTURES OF THE COMPLEXES OF SGPB WITH OMTKY3 AROMATIC P1 VARIANTS TRP18I, HIS18I, PHE18I AND TYR18I
2NU2E:16-236ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
2NU3E:16-236ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
2NU4E:16-236ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
2QA9E:16-236CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 4.2
2QAAB:16-236; B:16-236CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 7.3
2SGDE:16-236ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
2SGEE:16-236GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
2SGFE:16-236PHE 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
2SGPE:16-236PRO 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
2SGQE:16-236GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3SGBE:16-236STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEASE B AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR AT 1.8 ANGSTROMS RESOLUTION
3SGQE:16-236GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
1OS8A:16-238RECOMBINANT STREPTOMYCES GRISEUS TRYPSIN
1OSSA:16-238T190P STREPTOMYCES GRISEUS TRYPSIN IN COMPLEX WITH BENZAMIDINE
1SGTA:16-238REFINED CRYSTAL STRUCTURE OF STREPTOMYCES GRISEUS TRYPSIN AT 1.7 ANGSTROMS RESOLUTION
(-)
Sus scrofa (Pig) (47)
1JIMA:16-238STEREOSPECIFIC REACTION OF 3-METHOXY-4-CHLORO-7-AMINOISOCOUMARIN WITH CRYSTALLINE PORCINE PANCREATIC ELASTASE
1L0ZA:1-233THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE, CRYOPROTECTED WITH DRY PARAFFIN OIL
1LKAA:1-233PORCINE PANCREATIC ELASTASE/CA-COMPLEX
1LKBA:1-233PORCINE PANCREATIC ELASTASE/NA-COMPLEX
1LVYA:16-238PORCINE ELASTASE
1MCVA:16-238CRYSTAL STRUCTURE ANALYSIS OF A HYBRID SQUASH INHIBITOR IN COMPLEX WITH PORCINE PANCREATIC ELASTASE
1MMJN:1-233PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR, FR136706
1NESE:16-238STRUCTURE OF THE PRODUCT COMPLEX OF ACETYL-ALA-PRO-ALA WITH PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
1UO6A:1-233PORCINE PANCREATIC ELASTASE/XE-COMPLEX
1UVPA:1-233STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH CADMIUM REFINED AT 1.85 A RESOLUTION (CRYSTAL B)
2OQUA:1-233HIGH PRESSURE CRYOCOOLING OF CAPILLARY SAMPLE CRYOPROTECTION AND DIFFRACTION PHASING AT LONG WAVELENGTHS
2V0BA:1-233SAD STRUCTURE SOLUTION PORCINE PANCREATIC ELASTASE FROM A SELENATE DERIVATIVE
2V35A:16-238PORCINE PANCREATIC ELASTASE IN COMPLEX WITH INHIBITOR JM54
3MNBA:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. FIRST STAGE OF RADIATION DAMAGE
3MNCA:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. SECOND STAGE OF RADIATION DAMAGE
3MNSA:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. THIRD STAGE OF RADIATION DAMAGE
3MNXA:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. FOURTH STAGE OF RADIATION DAMAGE
3MO3A:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. FIFTH STAGE OF RADIATION DAMAGE
3MO6A:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. SIXTH STAGE OF RADIATION DAMAGE
3MO9A:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. SEVENTH STAGE OF RADIATION DAMAGE
3MOCA:16-238INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. EIGHTH STAGE OF RADIATION DAMAGE
3MTYA:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. FIRST STEP OF RADIATION DAMAGE
3MU0A:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. THIRD STEP OF RADIATION DAMAGE
3MU1A:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. FIFTH STEP OF RADIATION DAMAGE
3MU4A:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. FIRST STEP OF RADIATION DAMAGE
3MU5A:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. THIRD STEP OF RADIATION DAMAGE
3MU8A:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. FIFTH STEP OF RADIATION DAMAGE
3ODDA:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. SECOND STEP OF RADIATION DAMAGE
3ODFA:16-238COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES, 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. SECOND STEP OF RADIATION DAMAGE
1PFXC:16-237PORCINE FACTOR IXA
1X7AC:16-237PORCINE FACTOR IXA COMPLEXED TO 1-{3-[AMINO(IMINO) METHYL]PHENYL}-N-[4-(1H-BENZIMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE
2KAIB:95Y-238; B:95Y-238REFINED 2.5 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BY PORCINE KALLIKREIN A AND THE BOVINE PANCREATIC TRYPSIN INHIBITOR. CRYSTALLIZATION, PATTERSON SEARCH, STRUCTURE DETERMINATION, REFINEMENT, STRUCTURE AND COMPARISON WITH ITS COMPONENTS AND WITH THE BOVINE TRYPSIN-PANCREATIC TRYPSIN INHIBITOR COMPLEX
2PKAY:95Y-238; Y:95Y-238; Y:95Y-238; Y:95Y-238REFINED 2 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF PORCINE PANCREATIC KALLIKREIN A, A SPECIFIC TRYPSIN-LIKE SERINE PROTEINASE. CRYSTALLIZATION, STRUCTURE DETERMINATION, CRYSTALLOGRAPHIC REFINEMENT, STRUCTURE AND ITS COMPARISON WITH BOVINE TRYPSIN
1MCTA:16-238THE REFINED 1.6 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN PORCINE BETA-TRYPSIN AND MCTI-A, A TRYPSIN INHIBITOR OF SQUASH FAMILY
1S5SA:16-238PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1S6FA:16-238PORCINE TRYPSIN COVALENT COMPLEX WITH BORATE AND GUANIDINE-3 INHIBITOR
1S6HA:16-238PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1S81A:16-238PORCINE TRYPSIN WITH NO INHIBITOR BOUND
1S82A:16-238PORCINE TRYPSIN COMPLEXED WITH BORATE AND ETHYLENE GLYCOL
1S84A:16-238PORCINE TRYPSIN COVALENT COMPLEX WITH 4-AMINO BUTANOL, BORATE AND ETHYLENE GLYCOL
1S85A:16-238PORCINE TRYPSIN COMPLEXED WITH P-HYDROXYMETHYL BENZAMIDINE AND BORATE
1TFXB:16-238; B:16-238COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN
1TX6D:16-238; D:16-238; D:16-238; D:16-238TRYPSIN:BBI COMPLEX
1UHBB:146-238; B:146-238CRYSTAL STRUCTURE OF PORCINE ALPHA TRYPSIN BOUND WITH AUTO CATALYTICALY PRODUCED NATIVE PEPTIDE AT 2.15 A RESOLUTION
1YF4A:16-238CRYSTAL STRUCTURE OF TRYPSIN-VASOPRESSIN COMPLEX
1Z7KA:16-238CRYSTAL STRUCTURE OF TRYPSIN- OVOMUCOID TURKEY EGG WHITE INHIBITOR COMPLEX
3MYWB:16-238; B:16-238THE BOWMAN-BIRK TYPE INHIBITOR FROM MUNG BEAN IN TERNARY COMPLEX WITH PORCINE TRYPSIN
(-)
Family: Trypsin_2 (18)
(-)
Arabidopsis thaliana (Mouse-ear cress) (1)
3QO6C:157-296; C:157-296; C:157-296CRYSTAL STRUCTURE ANALYSIS OF THE PLANT PROTEASE DEG1
(-)
Escherichia coli (strain K12) (6)
2ZLEM:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881; M:4753-4881CRYO-EM STRUCTURE OF DEGP12/OMP
3MH4B:88-224; B:88-224HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
3MH5B:88-224; B:88-224HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
3MH7A:88-224HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
3OTPF:88-224; F:88-224; F:88-224; F:88-224; F:88-224; F:88-224CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
3OU0A:88-224RE-REFINED 3CS0
(-)
Homo sapiens (Human) (4)
3NUMA:204-342SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
3NWUC:204-342; C:204-342; C:204-342SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
3NZIA:204-342SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
1LCYA:49-187CRYSTAL STRUCTURE OF THE MITOCHONDRIAL SERINE PROTEASE HTRA2
(-)
Human astrovirus-1 (HAstV-1) (1)
2W5EF:447-565; F:447-565; F:447-565; F:447-565; F:447-565; F:447-565STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
(-)
Mycobacterium tuberculosis (2)
1Y8TC:33-183; C:33-183; C:33-183CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS-PROTEOLYTICALLY ACTIVE FORM
2Z9IC:33-183; C:33-183; C:33-183CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS-PROTEOLYTICALLY ACTIVE FORM
(-)
Staphylococcus aureus (1)
1WCZA:36-183CRYSTAL STRUCTURE OF AN ALKALINE FORM OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
(-)
Staphylococcus aureus (strain Mu50 / ATCC 700699) (2)
1QY6A:36-183STRUCTUE OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
2O8LA:36-183STRUCTURE OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
(-)
Thermotoga maritima (1)
1L1JB:81-220; B:81-220CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF AN ATP-INDEPENDENT HEAT SHOCK PROTEASE HTRA